Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1
Abstract Background Great progress has been made in applying immunotherapy to the clinical treatment of tumors. However, many patients with triple-negative breast cancer (TNBC) cannot benefit from immunotherapy due to the immune desert type of TNBC, which is unresponsive to immunotherapy. DMKG, a ce...
Main Authors: | Hongpei Tan, Jiahao Liu, Jing Huang, Yanan Li, Qiongxuan Xie, Yuqian Dong, Ze Mi, Xiaoqian Ma, Pengfei Rong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-07-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-023-04312-2 |
Similar Items
-
Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma
by: Le Li, et al.
Published: (2023-09-01) -
Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
by: Hsuan‐Chen Liu, et al.
Published: (2023-11-01) -
Regulating Effect of Exogenous α-Ketoglutarate on Ammonium Assimilation in Poplar
by: Xiaoning Liu, et al.
Published: (2024-03-01) -
PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
by: Duaa Alkaabi, et al.
Published: (2023-03-01) -
The physiological metabolite α-ketoglutarate ameliorates osteoarthritis by regulating mitophagy and oxidative stress
by: Liang Liu, et al.
Published: (2023-06-01)